No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240517C57500
- 4.20
- -1.80-30.00%
15min DelayClose May 8 14:59 ET
5.30High4.20Low
5.30Open6.00Pre Close49 Volume139 Open Interest57.50Strike Price23.56KTurnover91.70%IV4.18%PremiumMay 17, 2024Expiry Date2.25Intrinsic Value100Multiplier9DDays to Expiry1.95Time Value100Contract SizeAmericanOptions Type0.6229Delta0.0435Gamma12.58Leverage Ratio-0.1865Theta0.0083Rho7.83Eff Leverage0.0362Vega
Intraday
- 5D
- 1D
News
Express News | Exact Sciences Q1 Income From Operations USD -106.692 Million
Exact Sciences 1Q Loss/Shr 60c >EXAS
Exact Sciences 1Q Loss/Shr 60c >EXAS
Exact Sciences 1Q Rev $638M >EXAS
Exact Sciences 1Q Rev $638M >EXAS
Exact Sciences 1Q EBITDA Loss $47M >EXAS
Exact Sciences 1Q EBITDA Loss $47M >EXAS
Exact Sciences 1Q Loss $110M >EXAS
Exact Sciences 1Q Loss $110M >EXAS
Stocks Falter As Fed Signals Need For Higher-For-Longer Rates; Uber Crashes, Energy Sector Loses Ground: What's Driving Wednesday's Market?
Wednesday witnessed a tempering of the bullish sentiment that had buoyed Wall Street in recent sessions, with major indices showing slight declines around midday trading in New York.Hawkish remarks fr
Comments
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Read more